Article Examines Treatment for Children with Severe Therapy-Resistant Asthma

The September 2020 edition of The Lancet includes an article examining advances that have been made in “understanding the pathophysiology of severe therapy-resistant asthma in children.” The article looks closely at “mechanistic studies…” that “have led to the development of several biologics targeting type 2 inflammation,” which has potential to reduce asthma burdens, but requires “detailed assessment and characterization of each child with seemingly severe asthma.” The article suggests “risk stratification, remote monitoring, and the integration of multiple data sources could help to tailor management for the individual child with severe asthma.”

For more information and to view the article summary, click here.